Sandbox GGC2
From Proteopedia
(Difference between revisions)
| (One intermediate revision not shown.) | |||
| Line 14: | Line 14: | ||
Also, diseases of Human Hexokinase can also result in diseases that affect the nervous system. A nervous system disease associated with the protein is neuropathy, '''hereditary motor and sensory, Russe type (HMSNR)''', also known as '''Charcot-Marie-Tooth''' disease. Laboratory studies suggest that this disease is caused by a mutation in a 26 kb range in upstream exons in the Human Hexokinase 1 gene. HMSNR is also autosomal recessive and is usually apparent in the first 10 years of life, characterized by muscular atrophy and impairment in the distal lower limbs. This weakness and atrophy results in those affected by the disease experiencing difficulty walking. HMSNR can later develop into weakness in the distal upper limbs and the proximal lower limbs. It is suspected that this disease is a result of demyelination of the neuronal axon which in turn has negative effects on neuron action potential velocity <ref>PMID:19536174</ref>. | Also, diseases of Human Hexokinase can also result in diseases that affect the nervous system. A nervous system disease associated with the protein is neuropathy, '''hereditary motor and sensory, Russe type (HMSNR)''', also known as '''Charcot-Marie-Tooth''' disease. Laboratory studies suggest that this disease is caused by a mutation in a 26 kb range in upstream exons in the Human Hexokinase 1 gene. HMSNR is also autosomal recessive and is usually apparent in the first 10 years of life, characterized by muscular atrophy and impairment in the distal lower limbs. This weakness and atrophy results in those affected by the disease experiencing difficulty walking. HMSNR can later develop into weakness in the distal upper limbs and the proximal lower limbs. It is suspected that this disease is a result of demyelination of the neuronal axon which in turn has negative effects on neuron action potential velocity <ref>PMID:19536174</ref>. | ||
| - | Another nervous system disease is a '''neurodevelopmental disorder with visual defects and brain anomalies (NEDVIBA)'''. This disease is found to primarily impact the brain and is characterized by speech delay, intellectual disability, structural brain abnormalities, and visual impairments. The disease is caused by mutations in the 414 position (G → E), the 418 position (K → E), the 445 position (S → L), and in the 457 position (T → M) <ref>PMID:30778173</ref>. | + | Another nervous system disease is a '''neurodevelopmental disorder with visual defects and brain anomalies (NEDVIBA)'''. This disease is found to primarily impact the brain, eyes, and heart. NEDVIBA is characterized by speech delay, intellectual disability, structural brain abnormalities, and visual impairments. The disease is caused by mutations in the 414 position (G → E), the 418 position (K → E), the 445 position (S → L), and in the 457 position (T → M) <ref>PMID:30778173</ref>. |
'''Retinitis pigmentosa''' is also a disease caused by mutation of the <scene name='75/752269/Oliver_glu847/2'>Glutamate</scene> residue in the 847 positions to a Lysine in Human Hexokinase 1. This disease is an autosomal dominant disease. Retinitis pigmentosa is a form of retinal dystrophy and is characterized by retinal pigment deposits. There is also a loss of both the rod and cone photoreceptors in the eye. Patients typically experience visual difficulty in poorly lit environments and loss of the mid-peripheral visual field. As the condition progresses, patients continue to experience deterioration of the visual field <ref>PMID:25190649</ref><ref>PMID:25316723</ref>. | '''Retinitis pigmentosa''' is also a disease caused by mutation of the <scene name='75/752269/Oliver_glu847/2'>Glutamate</scene> residue in the 847 positions to a Lysine in Human Hexokinase 1. This disease is an autosomal dominant disease. Retinitis pigmentosa is a form of retinal dystrophy and is characterized by retinal pigment deposits. There is also a loss of both the rod and cone photoreceptors in the eye. Patients typically experience visual difficulty in poorly lit environments and loss of the mid-peripheral visual field. As the condition progresses, patients continue to experience deterioration of the visual field <ref>PMID:25190649</ref><ref>PMID:25316723</ref>. | ||
| Line 23: | Line 23: | ||
There are several relevant regions of importance in the Human Hexokinase 1 protein. The N-terminal spanning from residue 1-10, are responsible for the binding interaction between the Human Hexokinase 1 protein and the mitochondria<ref>PMID:1985912</ref>. Further, there are multiple Glucose-6-Phosphate binding domains. These binding domains are seen at residues <scene name='75/752269/Oliver_residues_84-91/1'>84-91</scene>, 413-415, 532-536, and 861-863. There are also multiple glucose binding sites present at residues <scene name='75/752269/Oliver_substrate_binding_site/1'>172-173</scene>, 208-209, and 291-294 <ref>PMID:9493266</ref><ref>PMID:9735292</ref><ref>PMID:10574795</ref><ref>PMID:10686099</ref>. | There are several relevant regions of importance in the Human Hexokinase 1 protein. The N-terminal spanning from residue 1-10, are responsible for the binding interaction between the Human Hexokinase 1 protein and the mitochondria<ref>PMID:1985912</ref>. Further, there are multiple Glucose-6-Phosphate binding domains. These binding domains are seen at residues <scene name='75/752269/Oliver_residues_84-91/1'>84-91</scene>, 413-415, 532-536, and 861-863. There are also multiple glucose binding sites present at residues <scene name='75/752269/Oliver_substrate_binding_site/1'>172-173</scene>, 208-209, and 291-294 <ref>PMID:9493266</ref><ref>PMID:9735292</ref><ref>PMID:10574795</ref><ref>PMID:10686099</ref>. | ||
| - | |||
</StructureSection> | </StructureSection> | ||
| - | |||
== References == | == References == | ||
| - | |||
<references/> | <references/> | ||
Current revision
1QHA HUMAN HEXOKINASE TYPE I
| |||||||||||
References
- ↑ Wolf AJ, Reyes CN, Liang W, Becker C, Shimada K, Wheeler ML, Cho HC, Popescu NI, Coggeshall KM, Arditi M, Underhill DM. Hexokinase Is an Innate Immune Receptor for the Detection of Bacterial Peptidoglycan. Cell. 2016 Jul 28;166(3):624-636. doi: 10.1016/j.cell.2016.05.076. Epub 2016 Jun , 30. PMID:27374331 doi:http://dx.doi.org/10.1016/j.cell.2016.05.076
- ↑ Magnani M, Serafini G, Bianchi M, Casabianca A, Stocchi V. Human hexokinase type I microheterogeneity is due to different amino-terminal sequences. J Biol Chem. 1991 Jan 5;266(1):502-5. PMID:1985912
- ↑ Garfinkel L, Garfinkel D. Magnesium regulation of the glycolytic pathway and the enzymes involved. Magnesium. 1985;4(2-3):60-72. PMID:2931560
- ↑ Wolf AJ, Reyes CN, Liang W, Becker C, Shimada K, Wheeler ML, Cho HC, Popescu NI, Coggeshall KM, Arditi M, Underhill DM. Hexokinase Is an Innate Immune Receptor for the Detection of Bacterial Peptidoglycan. Cell. 2016 Jul 28;166(3):624-636. doi: 10.1016/j.cell.2016.05.076. Epub 2016 Jun , 30. PMID:27374331 doi:http://dx.doi.org/10.1016/j.cell.2016.05.076
- ↑ Lau E, Kluger H, Varsano T, Lee K, Scheffler I, Rimm DL, Ideker T, Ronai ZA. PKCepsilon promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Cell. 2012 Feb 3;148(3):543-55. doi: 10.1016/j.cell.2012.01.016. PMID:22304920 doi:http://dx.doi.org/10.1016/j.cell.2012.01.016
- ↑ Bianchi M, Magnani M. Hexokinase mutations that produce nonspherocytic hemolytic anemia. Blood Cells Mol Dis. 1995;21(1):2-8. doi: 10.1006/bcmd.1995.0002. PMID:7655856 doi:http://dx.doi.org/10.1006/bcmd.1995.0002
- ↑ Hantke J, Chandler D, King R, Wanders RJ, Angelicheva D, Tournev I, McNamara E, Kwa M, Guergueltcheva V, Kaneva R, Baas F, Kalaydjieva L. A mutation in an alternative untranslated exon of hexokinase 1 associated with hereditary motor and sensory neuropathy -- Russe (HMSNR). Eur J Hum Genet. 2009 Dec;17(12):1606-14. doi: 10.1038/ejhg.2009.99. Epub 2009, Jun 17. PMID:19536174 doi:http://dx.doi.org/10.1038/ejhg.2009.99
- ↑ Okur V, Cho MT, van Wijk R, van Oirschot B, Picker J, Coury SA, Grange D, Manwaring L, Krantz I, Muraresku CC, Hulick PJ, May H, Pierce E, Place E, Bujakowska K, Telegrafi A, Douglas G, Monaghan KG, Begtrup A, Wilson A, Retterer K, Anyane-Yeboa K, Chung WK. De novo variants in HK1 associated with neurodevelopmental abnormalities and visual impairment. Eur J Hum Genet. 2019 Jul;27(7):1081-1089. doi: 10.1038/s41431-019-0366-9. Epub, 2019 Feb 18. PMID:30778173 doi:http://dx.doi.org/10.1038/s41431-019-0366-9
- ↑ Sullivan LS, Koboldt DC, Bowne SJ, Lang S, Blanton SH, Cadena E, Avery CE, Lewis RA, Webb-Jones K, Wheaton DH, Birch DG, Coussa R, Ren H, Lopez I, Chakarova C, Koenekoop RK, Garcia CA, Fulton RS, Wilson RK, Weinstock GM, Daiger SP. A dominant mutation in hexokinase 1 (HK1) causes retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2014 Sep 4;55(11):7147-58. doi: 10.1167/iovs.14-15419. PMID:25190649 doi:http://dx.doi.org/10.1167/iovs.14-15419
- ↑ Wang F, Wang Y, Zhang B, Zhao L, Lyubasyuk V, Wang K, Xu M, Li Y, Wu F, Wen C, Bernstein PS, Lin D, Zhu S, Wang H, Zhang K, Chen R. A missense mutation in HK1 leads to autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2014 Oct 14;55(11):7159-64. doi:, 10.1167/iovs.14-15520. PMID:25316723 doi:http://dx.doi.org/10.1167/iovs.14-15520
- ↑ Gauci S, Helbig AO, Slijper M, Krijgsveld J, Heck AJ, Mohammed S. Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem. 2009 Jun 1;81(11):4493-501. PMID:19413330 doi:http://dx.doi.org/10.1021/ac9004309
- ↑ Lundby A, Secher A, Lage K, Nordsborg NB, Dmytriyev A, Lundby C, Olsen JV. Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun. 2012 Jun 6;3:876. doi: 10.1038/ncomms1871. PMID:22673903 doi:http://dx.doi.org/10.1038/ncomms1871
- ↑ Magnani M, Serafini G, Bianchi M, Casabianca A, Stocchi V. Human hexokinase type I microheterogeneity is due to different amino-terminal sequences. J Biol Chem. 1991 Jan 5;266(1):502-5. PMID:1985912
- ↑ Aleshin AE, Zeng C, Bourenkov GP, Bartunik HD, Fromm HJ, Honzatko RB. The mechanism of regulation of hexokinase: new insights from the crystal structure of recombinant human brain hexokinase complexed with glucose and glucose-6-phosphate. Structure. 1998 Jan 15;6(1):39-50. PMID:9493266
- ↑ Aleshin AE, Zeng C, Bartunik HD, Fromm HJ, Honzatko RB. Regulation of hexokinase I: crystal structure of recombinant human brain hexokinase complexed with glucose and phosphate. J Mol Biol. 1998 Sep 18;282(2):345-57. PMID:9735292 doi:10.1006/jmbi.1998.2017
- ↑ Rosano C, Sabini E, Rizzi M, Deriu D, Murshudov G, Bianchi M, Serafini G, Magnani M, Bolognesi M. Binding of non-catalytic ATP to human hexokinase I highlights the structural components for enzyme-membrane association control. Structure. 1999 Nov 15;7(11):1427-37. PMID:10574795
- ↑ Aleshin AE, Kirby C, Liu X, Bourenkov GP, Bartunik HD, Fromm HJ, Honzatko RB. Crystal structures of mutant monomeric hexokinase I reveal multiple ADP binding sites and conformational changes relevant to allosteric regulation. J Mol Biol. 2000 Mar 3;296(4):1001-15. PMID:10686099 doi:10.1006/jmbi.1999.3494
